98%
921
2 minutes
20
Objective: To assess the prognostic significance of plasma fibrinogen(FIB) levels in patients of diffuse large B-cell lymphoma(DLBCL).
Methods: We retrospectively analyzed 203 newly diagnosed with DLBCL patients who met the study requirements from November 2016 to May 2024. Based on the receiver operating characteristic (ROC) curve analysis of plasma FIB levels during diagnosis, the critical value of FIB was determined, and patients were divided into high FIB and low FIB groups. The clinical characteristics and relevant laboratory indicators of two groups were compared. The impact of plasma FIB levels on overall survival (OS) were evaluated using Kaplan-Meier curves as well as univariate and multivariate Cox regression analysis. The differences in FIB and other laboratory indicators under different disease states were compared.
Results: According to the ROC curve, the optimal cut-off value of FIB was 3.49 g/L. Compared with the high FIB group (>3.49 g/L), the low FIB group (≤3.49 g/L) had a significant decrease in neutrophil count (ANC) ( =0.001) and platelet count (PLT) ( =0.027), and a significant increase in prealbumin (PA) ( =0.001). A high FIB level was associated with decreased OS ( =0.005). Univariate analysis results showed that FIB had an impact on survival of patients(=2.031,95% : 1.221-3.375, =0.006). Multivariate analysis showed that higher FIB level was an independent adverse prognostic factor affecting patients survival (=2.684, 95% :1.478-4.875, =0.001). Compared with patients with newly diagnosed or recurrent DLBCL, patients with complete remission showed a significant decrease in FIB ( < 0.001, =0.001) and ANC ( < 0.001, =0.021), as well as an increase in albumin (ALB) ( < 0.001, =0.018) and PA ( < 0.001, < 0.001).
Conclusion: Elevated FIB is a poor prognostic factor for DLBCL patients. The plasma FIB level is correlated with laboratory indicators such as ANC, PLT, PA, and disease status in DLBCL patients. Dynamic monitoring can assist in the early detection of changes in the condition.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2025.01.016 | DOI Listing |
Ann Hematol
September 2025
Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
To evaluate whether age modifies the association between the geriatric nutritional risk index (GNRI) and overall survival (OS) in patients aged ≥ 18 years with newly diagnosed diffuse large B-cell lymphoma (DLBCL), we conducted a multi-centre retrospective study of 552 patients. Multivariable Cox regression with restricted cubic spline (RCS) modelling showed that GNRI was significantly associated with OS, but the relationship was non-linear (P for non-linearity = 0.0158).
View Article and Find Full Text PDFMedicine (Baltimore)
September 2025
Department of Nuclear Medicine, Xi'an Gaoshang Medical Imaging Diagnosis Center, Xi'an, Shaanxi, China.
Diffuse large B-cell lymphoma (DLBCL) requires accurate therapeutic response assessment. This study evaluates the efficacy and prognostic value of [18F] fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) using the Deauville 5-point scale and maximum standardized uptake value (ΔSUVmax) methods in DLBCL patients. A retrospective study was conducted from January 2021 to December 2022, including 60 DLBCL patients.
View Article and Find Full Text PDFClin Case Rep
September 2025
Department of Radiation Oncology, School of Medicine, Shahid Rajayee Hospital Babol University of Medical Sciences Babol Iran.
Primary cardiac lymphoma (PCL) is one of the rarest primary malignancies of the heart. This report describes a rare presentation of diffuse large B-cell lymphoma (DLBCL) in a 61-year-old woman from Iran who presented with weakness, dyspnea, and bilateral lower extremity edema, especially on the right side that progressively worsened over 2 years. Initial diagnostic workup, including laboratory tests, color Doppler ultrasound, and echocardiography, revealed a large immobile mass attached to the RA wall.
View Article and Find Full Text PDFFront Immunol
September 2025
Department of Rheumatology and Immunology, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, China.
Background: The coexistence of neuropsychiatric systemic lupus erythematosus (NPSLE) and primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS) (PCNS DLBCL) is extremely rare in clinical practice. This article retrospectively analyzes the clinical manifestations, imaging examinations, pathological diagnosis, and treatment process of a patient with NPSLE, from the appearance of intracranial abnormal signal shadows to the final diagnosis of PCNS DLBCL.
Case Summary: A 32-year-old Chinese female patient had previously visited our hospital due to vomiting and delirium and was diagnosed with NPSLE.
Br J Haematol
September 2025
First Department of Medicine-Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Circulating tumour DNA (ctDNA) is a promising biomarker for diffuse large B-cell lymphoma (DLBCL) risk stratification and treatment response assessment, but real-world studies were limited. Using a targeted sequencing approach (521-gene panel), we showed that (1) baseline ctDNA level correlated with tumour burden and was an independent predictor of treatment outcome, (2) achievement of minimal residual disease (MRD) negativity was associated with a better treatment outcome and (3) interim MRD-positivity combined with positron emission tomography/computed tomography scan-positivity identified a high-risk subgroup of DLBCL patients. Baseline ctDNA level and treatment related achievement of MRD negativity are valuable prognostic tools in DLBCL to improve risk stratification in routine clinical practice.
View Article and Find Full Text PDF